JP2023062189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023062189A5 JP2023062189A5 JP2023027585A JP2023027585A JP2023062189A5 JP 2023062189 A5 JP2023062189 A5 JP 2023062189A5 JP 2023027585 A JP2023027585 A JP 2023027585A JP 2023027585 A JP2023027585 A JP 2023027585A JP 2023062189 A5 JP2023062189 A5 JP 2023062189A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- solid pharmaceutical
- compound
- pharmaceutical formulation
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000007787 solid Substances 0.000 claims 25
- 229940125904 compound 1 Drugs 0.000 claims 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 10
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 7
- 239000008199 coating composition Substances 0.000 claims 7
- 229960001021 lactose monohydrate Drugs 0.000 claims 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 7
- 229940079832 sodium starch glycolate Drugs 0.000 claims 7
- 239000008109 sodium starch glycolate Substances 0.000 claims 7
- 229920003109 sodium starch glycolate Polymers 0.000 claims 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 5
- 235000019359 magnesium stearate Nutrition 0.000 claims 5
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 3
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 229940033134 talc Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 229960005196 titanium dioxide Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080985P | 2014-11-17 | 2014-11-17 | |
| US62/080,985 | 2014-11-17 | ||
| US201562166572P | 2015-05-26 | 2015-05-26 | |
| US62/166,572 | 2015-05-26 | ||
| US201562251903P | 2015-11-06 | 2015-11-06 | |
| US62/251,903 | 2015-11-06 | ||
| JP2021008382A JP2021073241A (ja) | 2014-11-17 | 2021-01-22 | 癌を処置する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021008382A Division JP2021073241A (ja) | 2014-11-17 | 2021-01-22 | 癌を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023062189A JP2023062189A (ja) | 2023-05-02 |
| JP2023062189A5 true JP2023062189A5 (https=) | 2024-01-25 |
| JP7485810B2 JP7485810B2 (ja) | 2024-05-16 |
Family
ID=56014476
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526088A Active JP6829684B2 (ja) | 2014-11-17 | 2015-11-17 | 癌を処置する方法 |
| JP2021008382A Pending JP2021073241A (ja) | 2014-11-17 | 2021-01-22 | 癌を処置する方法 |
| JP2023027585A Active JP7485810B2 (ja) | 2014-11-17 | 2023-02-24 | 癌を処置する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526088A Active JP6829684B2 (ja) | 2014-11-17 | 2015-11-17 | 癌を処置する方法 |
| JP2021008382A Pending JP2021073241A (ja) | 2014-11-17 | 2021-01-22 | 癌を処置する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10786511B2 (https=) |
| EP (2) | EP3220916B1 (https=) |
| JP (3) | JP6829684B2 (https=) |
| KR (3) | KR20240035908A (https=) |
| CN (2) | CN107249591B (https=) |
| AU (3) | AU2015350108B2 (https=) |
| BR (1) | BR112017010166A2 (https=) |
| DK (1) | DK3220916T3 (https=) |
| EA (1) | EA201791095A1 (https=) |
| ES (1) | ES2947819T3 (https=) |
| FI (1) | FI3220916T3 (https=) |
| HU (1) | HUE062159T2 (https=) |
| IL (4) | IL296080B2 (https=) |
| LT (1) | LT3220916T (https=) |
| MX (2) | MX383484B (https=) |
| PL (1) | PL3220916T3 (https=) |
| PT (1) | PT3220916T (https=) |
| SG (1) | SG11201703806XA (https=) |
| SI (1) | SI3220916T1 (https=) |
| WO (1) | WO2016081523A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| CA2931263A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| IL285201B2 (en) | 2014-06-17 | 2024-05-01 | Epizyme Inc | EZH2 inhibitors for the treatment of lymphoma |
| HUE062159T2 (hu) * | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| CN108135908A (zh) | 2015-04-20 | 2018-06-08 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2017210395A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| TW201831181A (zh) | 2017-01-19 | 2018-09-01 | 日商第一三共股份有限公司 | 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | USE OF EZH2 INHIBITORS TO TREAT CANCER |
| WO2019050924A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | POLY THERAPY FOR THE TREATMENT OF CANCER |
| KR20220130698A (ko) * | 2019-12-20 | 2022-09-27 | 에피자임, 인코포레이티드 | Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물 |
| JP7628876B2 (ja) | 2021-04-23 | 2025-02-12 | 日立Astemo株式会社 | 情報処理装置、情報処理方法、プログラムおよび記憶媒体 |
| US20250146080A1 (en) * | 2022-02-17 | 2025-05-08 | Memorial Sloan-Kettering Cancer Center | Methods for overcoming tazemetostat-resistance in cancer patients |
| EP4514391A1 (en) | 2022-04-27 | 2025-03-05 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119052D0 (en) | 1991-09-06 | 1991-10-23 | Boots Co Plc | Pharmaceutical compositions |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20070026064A1 (en) * | 2005-07-29 | 2007-02-01 | Yoder Steven L | Pharmaceutical dosage forms having watermark-type identification and authentication inditia |
| WO2008121476A1 (en) * | 2007-03-28 | 2008-10-09 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
| US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| WO2012097222A1 (en) * | 2011-01-14 | 2012-07-19 | Bristol-Myers Squibb Company | High drug load tablet formulation of brivanib alaninate |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3363B1 (ar) * | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| RU2704445C2 (ru) | 2012-03-12 | 2019-10-28 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
| US9394283B2 (en) | 2012-04-13 | 2016-07-19 | Epizyme, Inc. | Salt form of a human histone methyltransferase EZH2 inhibitor |
| SG10201608579UA (en) * | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| CA2887243C (en) * | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| PE20150887A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
| US20150313906A1 (en) * | 2012-12-19 | 2015-11-05 | Glaxosmithkline Llc | Combination |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| WO2014100646A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| KR102142177B1 (ko) * | 2013-10-16 | 2020-08-07 | 에피자임, 인코포레이티드 | Ezh2 억제용 하이드로클로라이드 염 형태 |
| EP3057594A4 (en) * | 2013-10-18 | 2017-06-07 | Epizyme, Inc. | Method of treating cancer |
| CA2931263A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| IL285201B2 (en) * | 2014-06-17 | 2024-05-01 | Epizyme Inc | EZH2 inhibitors for the treatment of lymphoma |
| US20170217941A1 (en) | 2014-06-25 | 2017-08-03 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| IL310279A (en) | 2014-10-16 | 2024-03-01 | Epizyme Inc | Method for treating cancer |
| HUE062159T2 (hu) | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| EP3307713A4 (en) * | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
| EP3471830A4 (en) * | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
-
2015
- 2015-11-17 HU HUE15860676A patent/HUE062159T2/hu unknown
- 2015-11-17 IL IL296080A patent/IL296080B2/en unknown
- 2015-11-17 EA EA201791095A patent/EA201791095A1/ru unknown
- 2015-11-17 KR KR1020247007271A patent/KR20240035908A/ko active Pending
- 2015-11-17 KR KR1020217040314A patent/KR102644844B1/ko active Active
- 2015-11-17 PT PT158606764T patent/PT3220916T/pt unknown
- 2015-11-17 LT LTEPPCT/US2015/061194T patent/LT3220916T/lt unknown
- 2015-11-17 FI FIEP15860676.4T patent/FI3220916T3/fi active
- 2015-11-17 CN CN201580063476.2A patent/CN107249591B/zh active Active
- 2015-11-17 US US15/527,375 patent/US10786511B2/en active Active
- 2015-11-17 AU AU2015350108A patent/AU2015350108B2/en active Active
- 2015-11-17 MX MX2017006089A patent/MX383484B/es unknown
- 2015-11-17 JP JP2017526088A patent/JP6829684B2/ja active Active
- 2015-11-17 EP EP15860676.4A patent/EP3220916B1/en active Active
- 2015-11-17 SI SI201531949T patent/SI3220916T1/sl unknown
- 2015-11-17 IL IL304252A patent/IL304252B2/en unknown
- 2015-11-17 DK DK15860676.4T patent/DK3220916T3/da active
- 2015-11-17 PL PL15860676.4T patent/PL3220916T3/pl unknown
- 2015-11-17 SG SG11201703806XA patent/SG11201703806XA/en unknown
- 2015-11-17 CN CN202310518396.8A patent/CN116650500B/zh active Active
- 2015-11-17 EP EP23168326.9A patent/EP4272742A1/en active Pending
- 2015-11-17 BR BR112017010166-1A patent/BR112017010166A2/en not_active Application Discontinuation
- 2015-11-17 WO PCT/US2015/061194 patent/WO2016081523A1/en not_active Ceased
- 2015-11-17 ES ES15860676T patent/ES2947819T3/es active Active
- 2015-11-17 KR KR1020177016377A patent/KR102338802B1/ko active Active
-
2017
- 2017-05-09 MX MX2021006734A patent/MX2021006734A/es unknown
- 2017-05-09 IL IL252182A patent/IL252182B2/en unknown
-
2020
- 2020-08-20 US US16/998,144 patent/US12168014B2/en active Active
-
2021
- 2021-01-22 JP JP2021008382A patent/JP2021073241A/ja active Pending
- 2021-07-06 AU AU2021204706A patent/AU2021204706B2/en active Active
-
2023
- 2023-02-24 JP JP2023027585A patent/JP7485810B2/ja active Active
-
2024
- 2024-02-22 AU AU2024201171A patent/AU2024201171B2/en active Active
- 2024-11-08 US US18/941,480 patent/US20250064822A1/en active Pending
-
2025
- 2025-09-16 IL IL323396A patent/IL323396A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023062189A5 (https=) | ||
| HRP20250268T1 (hr) | Farmaceutska kombinacija i pripravak, te kombinirana priprema koja sadrži aktivator glukokinaze i hipoglikemički lijek biguanid kao i metoda pripreme i njihova uporaba | |
| JP6122098B2 (ja) | オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物 | |
| CN110719782A (zh) | 包含小分子egfr抑制剂的药物组合物及其制备方法 | |
| JP2017537899A5 (https=) | ||
| JP2019505525A (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| JP2021535908A5 (https=) | ||
| AU2018317472A1 (en) | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis | |
| WO2019036712A1 (en) | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS | |
| JP2016512234A (ja) | 薬学的複合製剤 | |
| JP2023528896A5 (https=) | ||
| WO2011161689A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| AU2023397768A1 (en) | Stat3 inhibitors for use in the treatment of non-viral liver cancer | |
| JP2023183393A (ja) | グアンファシン塩酸塩含有製剤 | |
| JP2015503555A (ja) | ボセンタン制御放出性経口製剤 | |
| EP4268806A1 (en) | A tablet comprising sacubitril and valsartan processed with dry granulation | |
| WO2018091609A1 (en) | Formulation comprising 4-methylpyrazole | |
| KR20120120519A (ko) | 나이아신 및 ＨＭＧ－ＣｏＡ 환원 효소 억제제를 포함하는 복합제제 및 그의 제조방법 | |
| WO2011081118A1 (ja) | 経口投与用医薬組成物 | |
| KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
| JP2023533903A (ja) | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 | |
| JP2020015690A (ja) | レボセチリジン含有錠剤 | |
| RU2020143136A (ru) | Фармацевтическая комбинация, композиция и комбинированный состав, содержащие активатор глюкокиназы и активатор рецептора ppar, и способ их приготовления и их применение | |
| RU2020143156A (ru) | Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и бигуанидное гипогликемическое лекарственное средство, а также способ их приготовления и их применение | |
| WO2023211412A1 (en) | A tablet comprising sacubitril and valsartan processed with dry granulation |